Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
A phase 3 trial of Pembrolizumab in melanoma, run by Iovance Biotherapeutics, Inc., now recruiting.
Overview
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. is a phase 3 interventional study registered as NCT05727904 by Iovance Biotherapeutics, Inc., with 670 participants planned, started 2023-03-30 and due to reach its primary completion in 2028-03-01. Interventions recorded: Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period. Conditions listed: Metastatic Melanoma, Unresectable Melanoma, Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Shares Iovance Biotherapeutics, Melanoma.
- TrialA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Shares Iovance Biotherapeutics, Melanoma.
- TrialA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
Shares Iovance Biotherapeutics, Melanoma.
- TrialC-144-01
Shares Iovance Biotherapeutics, Melanoma.
- IdeaSelect patients for cell therapy by whether their tumour holds reactive T cells
Shares Iovance Biotherapeutics, Melanoma.
- Key paperC-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed
Shares Iovance Biotherapeutics, Melanoma.
- TreatmentLifileucel
Shares Iovance Biotherapeutics, Melanoma.